Fox Chase Cancer Center News

Statement of Robert Uzzo, MD, MBA, FACS, Fox Chase Cancer Center President & CEO, on the death of Brian Kozera

PHILADELPHIA (August 17, 2022)—Brian Kozera lived his life according to a very simple, yet powerful mantra: Persevere, prevail.  A dear member of our Fox Chase Cancer Center community, Brian was a cancer survivor (or cancer thriver, as he would say), fundraiser, and friend who inspired us with his resolve, his passionate spirit, and his selfless dedication to others. It is with deep sadness that I share news of his unexpected passing on August 13 in a biking accident. Brian was 44.


Tarlatamab Shows Efficacy Against Metastatic Small Cell Lung Cancer in Phase 1 Study

PHILADELPHIA (August 8, 2022)—Patients with metastatic small cell lung cancer (SCLC) have limited options for treatment, with few drugs available for patients who have already completed frontline chemotherapy and immunotherapy. Now a global multi-institutional study that included researchers from Fox Chase Cancer Center has shown that the investigational drug tarlatamab is a promising new potential treatment for SCLC.


Fels Cancer Institute for Personalized Medicine, Fox Chase Cancer Center, and Thomas Jefferson University to Host Inaugural Symposium on Genome Instability and Personalized Medicine

PHILADELPHIA (August 4, 2022)—The Fels Cancer Institute for Personalized Medicine at the Lewis Katz School of Medicine at Temple University, in partnership with Fox Chase Cancer Center and Thomas Jefferson University, will host a free symposium, “Genome Instability: Discovery to Personalized Medicine.” This event will be held in person on Friday, October 14, 2022, at the DoubleTree by Hilton hotel in Philadelphia.